Fig. 3From: Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trialPFS of individual patients in the nivolumab group according to tumor PD-L1 expression, baseline blood NLR, and serum NaBack to article page